You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

HIVandHepatitis.com
 Google Custom Search

HCV Genotype 1 - 6
HCV Subtypes Variants

Genotype 1 and 4 Articles

Genotype 2 and 3 Articles

Genotype 5 and 6 Articles


 

Genotypes 1 and 4

Three-quarters of People with Hepatitis C in the U.S. Have Hard-to-treat Genotype 1
10/01/2010

Many Genotype 1 Hepatitis C Patients Can Be Cured with 24 Weeks of
Telaprevir plus Pegylated Interferon/ribavirin
4/28/2010

HCV Polymerase Inhibitor VX-222 Demonstrates Good Safety and Antiviral Activity in Treatment-naive Genotype 1 Hepatitis C Patients
4/23/2010

Experimental HCV Protease Inhibitor BI 201335 Shows Robust Antiviral Activity in Genotype 1 Non-responders
4/23/2010

Predictors of Rapid and Early Virological Response to Pegylated Interferon plus Ribavirin in Genotype 1 Hepatitis C Patients
4-9-2010

Older Hepatitis C Patients Have More Side Effects from Interferon-based Therapy, but Many Can Achieve Sustained Response
3/30/2010

Shorter Treatment May Be Adequate for Genotype 1 Hepatitis C If Started during Acute Infection
2/23/2010

Can Some Genotype 1 Chronic Hepatitis C Patients Benefit from Shorter Interferon-based Treatment?
2/16/2010

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09

Genotype 1 Chronic Hepatitis C Patients with Low Viral Load Can Achieve Sustained Response with 24 Weeks of Pegylated Interferon plus Ribavirin
11/17/09

InterMune and Roche Begins Trial of Ritonavir-boosted ITMN-191 (RG7227) for Genotype 1 Chronic Hepatitis C Patients

10/06/09

Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin
6/23/09


Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/05/09

Pegylated Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based Ribavirin Dosage

4/07/09


Widespread Hepatitis C Treatment Has Led to a Shift in HCV Genotypes in Spain

3/27/2009

Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients
2/03/2009


Genotype 1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of Pegylated Interferon plus Ribavirin
11/18/2008

Response to Pegylated Interferon plus Ribavirin in Asian Patients with Genotype 1 Chronic Hepatitis C
10/21/2008

24 Weeks of Pegylated Interferon plus Ribavirin May Be Sufficient for Selected Genotype 1/4 Chronic Hepatitis C Patients with Rapid Response
10/14/08


74 Percent of Genotype 1 HCV Patients in Experimental HCV PI Boceprevir Phase II Study Achieve Sustained Virologic Response (SVR) at 48 Weeks
8/05/2008


Adequate Ribavirin Exposure after the First Dose Predicts Sustained Virological Response to Hepatitis C Treatment in Genotype 1 Patients
7/08/08


HCV Genotype 1 Patients with High Viral Load Do Better with 48 vs 24 Weeks of Treatment, despite Rapid Virological Response
7/04/08





Genotypes 2 and 3


Can Chronic Hepatitis C Patients with Genotypes 2 or 3 Benefit from Shorter Interferon Treatment?
10/26/2010


Experimental HCV Polymerase Inhibitor RG7128 Is Effective with Standard Therapy in Genotype 2/3 Patients
4/23/2010

Older Hepatitis C Patients Have More Side Effects from Interferon-based Therapy, but Many Can Achieve Sustained Response
3/30/2010

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09

HCV Genotype 3 May Be Associated with More Rapid Liver Fibrosis Progression in People with Chronic Hepatitis C
10-27-2009

Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy
6-16-2009


Reduced Dose and Duration of PegIntron plus Ribavirin Is Not as Effective as Standard Therapy for Genotype 2 and 3 Hepatitis C Patients
5-29-2009


Widespread Hepatitis C Treatment Has Led to a Shift in HCV Genotypes in Spain

3/27/2009


Combination Therapy with Investigational HCV Polymerase Inhibitor R7128 Produces Rapid Response in Patients with Genotype 2/3 HCV
9/12/2008


Body Weight Affects Relapse Rates in Latinos with Genotype 2/3 Hepatitis C Treated with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin
8/12/2008


Eight Weeks of Pegylated Interferon plus Ribavirin for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR)
8/05/2008


12- Versus 24-week Treatment with Pegylated Interferon plus Ribavirin for Genotype 2 or 3 Chronic Hepatitis C Patients
7/11/08


European Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid Responders with HCV Genotypes 2 or 3 and Low Viral Load
7/04/08


Studies Explore Lower Doses of Pegylated Interferon and Ribavirin for People with Hepatitis C Virus Genotypes 2 or 3
7/08/08


Limitations of an 8-week Course of Pegylated interferon plus Ribavirin for Genotype 2 Hepatitis C Patients with Rapid Virological Response
4/24/08


Genetic Variations in HCV Genotype 3 Core Protein Promote Liver Fat Accumulation
2/26/08


Genotypes 5 and 6 Articles
(Genotype 5 - Africa / Genotype 6 - South East Asia)

Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy
12/01/09

Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6
6-19-2009


Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6
6/19/2009

Widespread Hepatitis C Treatment Has Led to a Shift in HCV Genotypes in Spain

3/27/2009


Individuals with HCV Genotype 6 Respond Well to Pegylated Interferon plus Ribavirin
10/14/08

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 
Experimental Treatments
Treatment Guidelines

HCV Articles by Topic

Cirrhosis
Fibrosis
Hepatocellular Carcinoma
Liver Transplantation
Liver Biopsy

Steatosis
Anemia
Children / Infants / Women
Drug Abuse
Experimental Treatments
FAQs About Hepatitis C
Genotypes
Insulin Resistance / Diabetes
Sustained Viral Response (SVR)
Tests for HCV
Vaccines for HCV